200 related articles for article (PubMed ID: 19592363)
21. Bronchopulmonary Dysplasia Within and Beyond the Neonatal Unit.
Khetan R; Hurley M; Spencer S; Bhatt JM
Adv Neonatal Care; 2016 Feb; 16(1):17-25;quiz E1-2. PubMed ID: 26734814
[TBL] [Abstract][Full Text] [Related]
22. Surfactant replacement in preterm infants with respiratory distress syndrome.
Dani C
Acta Biomed; 2012; 83 Suppl 1():17-20. PubMed ID: 23029871
[TBL] [Abstract][Full Text] [Related]
23. Lung function tests in neonates and infants with chronic lung disease: forced expiratory maneuvers.
Lum S; Hülskamp G; Merkus P; Baraldi E; Hofhuis W; Stocks J
Pediatr Pulmonol; 2006 Mar; 41(3):199-214. PubMed ID: 16288484
[TBL] [Abstract][Full Text] [Related]
24. Surfactant in the preterm infant: what's going on.
Dani C; Barp J; Berti E; Bertini G
J Matern Fetal Neonatal Med; 2009; 22 Suppl 3():3-5. PubMed ID: 19925357
[TBL] [Abstract][Full Text] [Related]
25. Surfactant replacement in neonates with early chronic lung disease.
Pandit PB; Dunn MS; Kelly EN; Perlman M
Pediatrics; 1995 Jun; 95(6):851-4. PubMed ID: 7761208
[TBL] [Abstract][Full Text] [Related]
26. Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study.
Ballard HO; Anstead MI; Shook LA
Respir Res; 2007 Jun; 8(1):41. PubMed ID: 17550598
[TBL] [Abstract][Full Text] [Related]
27. Bronchopulmonary dysplasia.
Deakins KM
Respir Care; 2009 Sep; 54(9):1252-62. PubMed ID: 19712501
[TBL] [Abstract][Full Text] [Related]
28. Randomized, double-blinded trial of low-dose dexamethasone: II. Functional residual capacity and pulmonary outcome in very low birth weight infants at risk for bronchopulmonary dysplasia.
McEvoy C; Bowling S; Williamson K; McGaw P; Durand M
Pediatr Pulmonol; 2004 Jul; 38(1):55-63. PubMed ID: 15170874
[TBL] [Abstract][Full Text] [Related]
29. Death postponement and increased chronic lung disease: the hidden costs of mortality reduction in the post-surfactant era.
Wright K
J Assoc Acad Minor Phys; 1999; 10(4):82-7. PubMed ID: 10826014
[TBL] [Abstract][Full Text] [Related]
30. Effects of intrauterine infection or inflammation on fetal lung development.
Westover AJ; Moss TJ
Clin Exp Pharmacol Physiol; 2012 Sep; 39(9):824-30. PubMed ID: 22816773
[TBL] [Abstract][Full Text] [Related]
31. Very early surfactant without mandatory ventilation in premature infants treated with early continuous positive airway pressure: a randomized, controlled trial.
Rojas MA; Lozano JM; Rojas MX; Laughon M; Bose CL; Rondon MA; Charry L; Bastidas JA; Perez LA; Rojas C; Ovalle O; Celis LA; Garcia-Harker J; Jaramillo ML;
Pediatrics; 2009 Jan; 123(1):137-42. PubMed ID: 19117872
[TBL] [Abstract][Full Text] [Related]
32. Neonatal chronic lung disease and exogenous surfactant therapy.
Greenough A
Eur J Pediatr; 1998 Jan; 157 Suppl 1():S16-8. PubMed ID: 9462901
[TBL] [Abstract][Full Text] [Related]
33. Delivery room continuous positive airway pressure/positive end-expiratory pressure in extremely low birth weight infants: a feasibility trial.
Finer NN; Carlo WA; Duara S; Fanaroff AA; Donovan EF; Wright LL; Kandefer S; Poole WK;
Pediatrics; 2004 Sep; 114(3):651-7. PubMed ID: 15342835
[TBL] [Abstract][Full Text] [Related]
34. Old and new uses of surfactant.
Gizzi C; Papoff P; Barbàra CS; Cangiano G; Midulla F; Moretti C
J Matern Fetal Neonatal Med; 2010 Oct; 23 Suppl 3():41-4. PubMed ID: 20836732
[TBL] [Abstract][Full Text] [Related]
35. Decreased incidence of bronchopulmonary dysplasia after early management changes, including surfactant and nasal continuous positive airway pressure treatment at delivery, lowered oxygen saturation goals, and early amino acid administration: a historical cohort study.
Geary C; Caskey M; Fonseca R; Malloy M
Pediatrics; 2008 Jan; 121(1):89-96. PubMed ID: 18166561
[TBL] [Abstract][Full Text] [Related]
36. Bronchopulmonary dysplasia - prevalence, severity and predictive factors in a national cohort of extremely premature infants.
Farstad T; Bratlid D; Medbø S; Markestad T;
Acta Paediatr; 2011 Jan; 100(1):53-8. PubMed ID: 20653607
[TBL] [Abstract][Full Text] [Related]
37. Is the use of early nasal CPAP associated with lower rates of chronic lung disease and retinopathy of prematurity? Nine years of experience with the Vermont Oxford Neonatal Network.
Kirchner L; Weninger M; Unterasinger L; Birnbacher R; Hayde M; Krepler R; Pollak A
J Perinat Med; 2005; 33(1):60-6. PubMed ID: 15841616
[TBL] [Abstract][Full Text] [Related]
38. Is there a strategy for preventing bronchopulmonary dysplasia? Absence of evidence is not evidence of absence.
Aly H
Pediatrics; 2007 Apr; 119(4):818-20. PubMed ID: 17403854
[No Abstract] [Full Text] [Related]
39. Oxygen use for preterm infants: factors that may influence clinical decisions surrounding oxygen titration.
Johnson K; Scott SD; Fraser KD
Adv Neonatal Care; 2011 Feb; 11(1):8-14; quiz 15-6. PubMed ID: 21285649
[TBL] [Abstract][Full Text] [Related]
40. Plasma biomarkers of oxidative stress: relationship to lung disease and inhaled nitric oxide therapy in premature infants.
Ballard PL; Truog WE; Merrill JD; Gow A; Posencheg M; Golombek SG; Parton LA; Luan X; Cnaan A; Ballard RA
Pediatrics; 2008 Mar; 121(3):555-61. PubMed ID: 18310205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
